Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial

Fertility and Sterility

Volumn 86, Issue 4, 2006, Pages 830-838

  Serafini, Paulo ^a,c   Yadid, Isaac ^b   Motta, Eduardo L A ^a,c,d   Alegretti, Jose R ^a   Fioravanti, Joyce ^a   Coslovsky, Marcio ^b  

^a Huntington Reproductive Medicine   (Brazil)

^b Huntington Reproductive Medicine   (Brazil)

^c Center for Human Reproduction Hospital and Maternity Santa Joana   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

in vitro fertilization; low dose hCG; Ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; CELL MATURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEMALE; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY; OVARY FOLLICLE CELL; OVARY HYPERSTIMULATION; OVULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CHORIONIC GONADOTROPIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMANS; OVARIAN FOLLICLE; OVULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; TREATMENT OUTCOME;

EID: 33749265289     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.02.110     Document Type: Article

References (24)

1. Filicori M., Cognigni G.E., Taraborrelli S., Spettoli D., Ciampaglia W., Tabarelli de Fatis C., et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 84 (1999) 2659-2663
2. Filicori M., and Cognigni G.E. Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction. J Clin Endocrinol Metab 86 (2001) 1437-1441
3. Filicori M., Cognigni G.E., Tabarelli C., Pocognoli P., Taraborrelli S., Spettoli D., et al. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 87 (2002) 1156-1161
4. Filicori M., Cognigni G.E., Pocognoli P., Tabarelli C., Spettoli D., Taraborrelli S., et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod 17 (2002) 2009-2015
5. Filicori M., Cognigni G.E., Gamberini E., Parmegiani L., Troilo E., and Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 84 (2005) 394-401
6. Thompson K.A., LaPolt P.S., and River J. Gonadotropin requirements of the developing follicle. Fertil Steril 63 (1995) 273-276
7. Fauser B.C., and Van Heusden A.M. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 18 (1997) 71-106
8. Sullivan M.W., Stewart-Akers A., Krasnow J.S., Berga S.L., and Zeleznik A.J. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 84 (1999) 228-232
9. Filicori M., Cognigni G.E., Taraborrelli S., Spettoli D., Ciampaglia W., Tabarelli de Fatis C., et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 86 (2001) 337-343
10. Filicori M., Cognigni G.E., Taraborrelli S., Spettoli D., Ciampaglia W., and Tabarelli de Fatis C. Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. Fertil Steril 72 (1999) 1118-1120
11. Filicori M., Cognigni G.E., Taraborrelli S., Parmegiani L., Bernardi L., and Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril 78 (2002) 414-416
12. Serafini P., Nelson J., Batzofin J., and Olive D. Preovulatory sonographic uterine receptivity index (SURI): usefulness as an indicator of pregnancy in women undergoing assisted reproductive treatments. J Ultrasound Med 14 (1995) 751-755
13. Alves da Motta E.L., Alegretti J.R., Baracat E.C., Olive D., and Serafini P.C. High implantation and pregnancy rates with transfer of human blastocysts developed in preimplantation stage one and blastocyst media. Fertil Steril 70 (1998) 659-663
14. Huisman G.J., Fauser B.C., Eijkemans M.J., and Pieters M.H. Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertil Steril 73 (2000) 117-122
15. Aboulghar M.A., and Mansour R.T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 9 (2003) 275-289
16. Ubaldi F., Camus M., Smitz J., Bennink H.C., Van Steirteghem A., and Devroey P. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and a GnRH-a and urinary FSH. Fertil Steril 66 (1996) 275-280
17. The Ganirelix Dose-Finding Study Group. A double-blind, randomised, dose-finding study to assess the efficacy of the GnRH antagonist Ganirelix (org 37462) to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recombinant FSH (Puregon). Hum Reprod 13 (1998) 3023-3031
18. Borm G., Mannaerts B., and The European Orgalutran Study Group. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 15 (2000) 1490-1498
19. Stokman P.G., de Leeuw R., van den Wijngaard H.A., Kloosterboer H.J., Vemer H.M., and Sanders A.L. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 60 (1993) 175-178
20. Albano C., Felberbaum R.E., Smitz J., Riethmuller-Winzen H., Engel J., Diedrich K., et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 15 (2000) 526-531
21. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16 (2001) 644-651
22. Hohmann F.P., Macklon N.S., and Fauser B.C.J.M. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88 (2003) 166-173
23. Tesarik J., Hazout A., and Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 7 (2003) 59-64
24. Society for Assisted Reproductive Technology and The American Society for Reproductive Medicine. Assisted Reproductive Technology in the United States: 2000 results generated for the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 81 (2004) 1207-1220